Shire Collaboration Brings Validation To ArmaGen’s Drug-Delivery Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
While awaiting finalization of its merger with AbbVie, Shire signed a deal with privately held ArmaGen to license technology that could enable Elaprase to be delivered across the blood-brain barrier. That would enable the Hunter syndrome therapy to treat CNS manifestations of the disease as well as systemic symptoms.